Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Energex Systems has received approval from the FDA to utilize its experimental HemoModulation therapy in a clinical trial of HIV infected patients.
Subscribe to our email newsletter
The purpose of the study will be to demonstrate safety and monitor viral load changes in patients who are not yet eligible for antiviral drug therapy.
Energex Systems’s HemoModulation therapy is said to be an extracorporeal treatment that involves exposing a small amount of an infected subject’s blood (3-4%) to a precise amount of ultra-violet light, for a precise amount of time.
Thomas Fagan, CEO and president of Energex Systems, said: “We believe our HemoModulator technology and the therapy it provides is extremely promising in the fight against HIV/AIDS, hepatitis C and other RNA type viruses.”